Twist Bioscience Corp vs Teucrium Wheat Fund — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Teucrium Wheat Fund trades at $26.26. Which is the better fit depends on your goals.
| TWST | WEAT | |
|---|---|---|
Market Cap | $8.42B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $153.10 | $28.00 |
52-Week Low | $24.16 | $19.88 |
Enterprise Value | $8.35B | — |
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
WEAT, a US-listed wheat ETF, trades at $26.96, up 1.77% today, with a bullish technical signal from moving averages and ADX indicating strong trend momentum. Recent performance shows a 9.9% gain over the past month, driven by inflation concerns and commodity strength. Key support and resistance cluster around $27, suggesting a pivotal price zone.
Outlook remains positive due to inflation hedging demand, but risks include commodity price volatility and Federal Reserve policy shifts. The ETF lacks traditional fundamental metrics like P/E or revenue, relying on wheat futures performance. Investors should weigh macroeconomic trends against potential pullbacks in agricultural markets.
Trailing returns across standard periods
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →